Rubicon Water Limited Revenue Breakdown – ASX:RWL
NiveshIQ
NSE: RUBICON · Healthcare
Rubicon Research Ltd.
₹1,527.60▼ ₹8.00 (-0.52%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on RUBICON. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Rubicon Research Ltd.
Rubicon Research Limited is a specialty pharmaceutical company operating in India, the United States, and internationally. Its primary proprietary technologies, RubiSRL and RubiReten, enable the formulation of sustained release liquids and gastro-retentive systems for drugs with poor solubility. The company develops products across various therapeutic areas, including analgesics, gastrointestinal, cardiovascular, and central nervous system. With a strong presence in the Indian market, Rubicon Research has been expanding its global footprint. Recent developments, including a 15% jump in stock price and strong Q4 performance, have garnered significant attention from investors. The company's FY26 net profit rose 84% to ₹2.47 billion, driven by its diversified product portfolio and growing mar
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹854.00 Cr +116.80% | ₹1,284 Cr +50.40% | ₹1,754 Cr +36.60% |
| EBITDA Margin | 18.15% | 19.94% | 23.26% |
| Net Profit | ₹91.00 Cr | ₹134.00 Cr +47.30% | ₹246.73 Cr +84.10% |
| EPS | ₹5.98 | ₹8.72 | ₹15.52 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Rubicon Research Limited Revenue Breakdown – NSE:RUBICON
Price to earnings forward of Rubicon Water Limited – ASX:RWL
🔒
+ 3 more stories about Rubicon Research Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹514 Cr, PAT ₹77 Cr, EPS ₹4.66, EBITDA margin 23.6%. Growth context: revenue QoQ +8.0%, PAT QoQ +5.2%. Street verdict: beat, revenue surprise +1.8%, PAT surprise +5.8%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and R&D investments and te...
FY26 (last completed FY): revenue ₹1, 754 Cr, PAT ₹247 Cr, EBITDA margin 23.3%, EPS ₹15.52. Year-on-year: revenue YoY +3...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for RUBICON
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track RUBICON alongside your other holdings
Unlock full RUBICON research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Rubicon Research Ltd.?
NiveshIQ detects active intelligence signals for Rubicon Research Ltd. (RUBICON) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Rubicon Research Ltd.?
Rubicon Research Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,563,562.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.